Additional file 6: Figure S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Incremental cost per responder over 24 weeks among the biologic-naïve population. (A) Incremental cost per additional ACR50 responder vs. Incremental cost per additional PASI75 responder. (B) Incremental cost per additional ACR70 responder vs. Incremental cost per additional PASI90 responder. PASI responses were not reported for certolizumab pegol or apremilast in the biologic-naïve population. ADA, adalimumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; UST 45, ustekinumab 45 mg; UST 90, ustekinumab 90 mg. (TIFF 105 kb